Equities

Raia Drogasil S/A

Raia Drogasil S/A

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (BRL)25.92
  • Today's Change0.55 / 2.17%
  • Shares traded1.79m
  • 1 Year change-8.73%
  • Beta0.6122
Data delayed at least 15 minutes, as of Nov 22 2024 18:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Raia Drogasil SA is a Brazil-based company engaged in retail sales of medications, specialty medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. The Company’s sales are carried out by over 860 stores, located in the states of Sao Paulo, Minas Gerais, Rio de Janeiro, Parana, Goias, Espirito Santo, Santa Catarina, Rio Grande do Sul, Bahia, Mato Grosso and Mato Grosso do Sul and in the Distrito Federal. The Company operates through a range of subsidiaries, such as Raia SA and 4-Bio Medicamentos SA.

  • Revenue in BRL (TTM)37.70bn
  • Net income in BRL1.11bn
  • Incorporated1935
  • Employees62.40k
  • Location
    Raia Drogasil S/AAv. Corifeu de Azevedo Marques3.097, ButantaSAO PAULO 05.339-900BrazilBRA
  • Phone+55 1 137695678
  • Fax+55 1 137695687
  • Websitehttps://rdsaude.com.br/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sendas Distribuidora SA72.08bn636.00m9.38bn80.00k14.831.884.180.13020.46790.467953.113.691.698.3649.59900,962.501.49--2.50--16.48--0.8824--0.42571.270.8386--21.98---41.80------
Atacadao SA113.95bn25.00m13.31bn95.67k539.780.67076.380.11680.01170.011754.069.411.297.0830.17--0.27612.850.54965.8018.4819.340.21332.110.63572.450.507546.716.7715.15-145.72--14.43-15.92
Grupo Mateus SA30.90bn1.32bn15.86bn29.67k11.751.678.270.51310.59740.597413.984.201.884.409.69--8.109.1010.9811.6122.3422.854.324.870.95239.640.2898--22.9931.2216.0032.5449.67--
Raia Drogasil S/A37.70bn1.11bn43.59bn62.40k38.026.9014.761.160.66730.667322.543.671.823.5112.44653,501.505.515.789.399.2529.8329.923.023.330.51173.280.54944.2516.8818.085.9115.9913.1620.02
Data as of Nov 22 2024. Currency figures normalised to Raia Drogasil S/A's reporting currency: Brazilian Real BRL

Institutional shareholders

20.10%Per cent of shares held by top holders
HolderShares% Held
Schroder Investment Management Ltd.as of 30 Sep 202457.94m3.37%
RBC Global Asset Management (UK) Ltd.as of 30 Sep 202452.58m3.06%
The Vanguard Group, Inc.as of 06 Nov 202442.51m2.47%
BlackRock Fund Advisorsas of 07 Nov 202438.44m2.24%
Invesco Advisers, Inc.as of 14 Nov 202434.75m2.02%
Fidelity Management & Research Co. LLCas of 30 Sep 202432.18m1.87%
Wasatch Advisors LPas of 30 Sep 202424.53m1.43%
JPMorgan Asset Management (UK) Ltd.as of 08 Nov 202424.48m1.43%
JPMorgan Investment Management, Inc.as of 07 Nov 202420.63m1.20%
Sands Capital Management LLCas of 31 Oct 202417.19m1.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.